NasdaqGS:INDVPharmaceuticals
Why Indivior Pharmaceuticals (INDV) Is Up 9.8% After Raising 2026 Revenue Guidance And Earnings
In the past week, Indivior Pharmaceuticals, Inc. reported Q1 2026 results showing sales of US$317 million and net income of US$89 million, with basic earnings per share from continuing operations rising to US$0.71 from US$0.38 a year earlier.
Alongside this performance, the company raised its 2026 net revenue guidance to a range of US$1.22 billion to US$1.29 billion, underscoring how momentum in SUBLOCADE and tighter cost control are reshaping expectations for earnings power and capital...